ReviewCell communication and signaling : CCS2026
Therapeutic potential of cytokine-induced killer cell therapy for renal cell carcinoma and prostate cancer.
Review in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multidisciplinary treatment incorporating autologous DC-CIK cell therapy induces long-term survival in advanced pancreatic cancer: a case report.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Renal cell carcinoma (RCC) and prostate cancer (PCa) are among the most prevalent and therapeutically challenging malignancies of the genitourinary system, particularly in advanced or metastatic stages. For advanced/metastatic RCC, targeted agents such as tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) have improved progression-free and overall survival. For metastatic castration-sensitive PCa, androgen deprivation therapy (ADT) combined androgen receptor pathway inhibitors (ARPIs) with or without chemotherapy remains the standard of care. Despite these advances, therapeutic resistance, tumor recurrence, and treatment-related toxicities continue to limit long-term outcomes. Therefore, innovative immunotherapeutic strategies that can strengthen antitumor immunity, reduce relapse, and improve survival are urgently required. Cytokine-induced killer (CIK) cell therapy has emerged as a promising adoptive immunotherapy capable of enhancing antitumor immunity and improving outcomes. CIK cells are a heterogeneous population of immune effectors sharing features of T cells (CD3⁺CD56⁻), NK-like T cells (CD3⁺CD56⁺), and NK cells (CD3⁻CD56⁺). Their cytotoxic activity occurs in a major histocompatibility complex (MHC)-unrestricted manner through natural killer group 2 member D (NKG2D) receptor-ligand interactions, enabling the elimination of a wide spectrum of tumor types. In addition to their simple preparation, strong proliferative capacity, and low cost, CIK therapy offers several advantages, including reduced relapse rates, improved quality of life, prolonged survival, and favorable safety and tolerability. The versatility of CIK cells also allows integration with existing immunotherapies and targeted treatments. This review highlights recent advances in CIK cell therapy for RCC and PCa, emphasizing their biological mechanisms, preclinical and clinical evidence, and future perspectives for clinical translation and combination immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.